ascopubs.org24d
Spotlight on Lung Cancer Disparities in India
The India State-Level Disease Burden Initiative partners revealed significant variation in age-standardized incidence of the top 10 malignancies, including LC from 1990 to 2016. In men, the crude LC ...
ascopubs.org13d
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma A total of 121 patients (previous ICI-treated cohort, n = 31, and each of ...
ascopubs.org2d
Baseline fracture risk for prostate cancer patients initiating long-term androgen deprivation therapy.
Efficacy of 177Lu-PSMA-617 with or without ARPIs for the treatment of mCRPC: VISION secondary analysis. Safety profile of lutetium-177 in patients with impaired renal function: A retrospective ...
ascopubs.org6d
Where Is the Future of Adjuvant Therapy for Hepatocellular Carcinoma?
Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3 The following represents disclosure information provided by authors of this manuscript ...
ascopubs.org13d
Impact of liquid biopsies on early detection, monitoring, and prognostication in prostate cancer: A meta-analysis of emerging evidence.
Novel urine-enriched RNA panel (EPCAM, TTC3, H4C5) to detect prostate cancer and differentiate it from benign prostatic disease. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary ...
ascopubs.org11d
Erratum: Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights
How Should We Manage the Impact of Antimicrobial Resistance in Patients With Cancer? An Oncological and Infectious Disease Specialist Point of View ...
ascopubs.org12d
Reply to: Enfortumab Vedotin: A Promising Therapy for Head and Neck Cancer With Potential Links to Human Papillomavirus
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
ascopubs.org4d
Erratum: Comparison of PREMM5 and PREMMplus Risk Assessment Models to Identify Lynch Syndrome
The article by Biller et al entitled “Comparison of PREMM5 and PREMMplus Risk Assessment Models to Identify Lynch Syndrome” (JCO Precision Oncology 10.1200/PO-24 ...
ascopubs.org13d
Treatment patterns in prostate cancer patients who received darolutamide in the ARAMIS trial in Spain: PARASEC study.
Metastasis-directed therapy (MDT) plus androgen deprivation therapy (ADT) for oligometastatic prostate cancer (omPC): Primary results of the EXTEND continuous ADT (cADT) basket plus combined analysis ...
ascopubs.org13d
Digital physiological monitoring for personalized prediction of physical function and fatigue in men with castration sensitive prostate cancer.
Safety profile of lutetium-177 in patients with impaired renal function: A retrospective analysis of adverse events in mCRPC treatment. This is an ASCO Meeting Abstract from the 2025 ASCO ...
ascopubs.org13d
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts Data were from a retrospective chart review of patients with ...